On 1 January 2021 the UK regulator, the MHRA, will launch a new licensing pathway for innovative drugs that will include an “innovative medicine designation” and a new “target development profile” for each product to act as a roadmap for its development.
The new pathway, which envisages “supervised early use” of new products through “adaptive authorization,” is part of a new, integrated...








